A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)
Status:
Terminated
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
A study to evaluate the safety, tolerability and efficacy of once daily Raltegravir compared
to twice daily raltegravir when each is given in combination with TRUVADA™ in treatment-naïve
human immunodeficiency virus (HIV)-infected patients.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Raltegravir Potassium